The Early Detection Research Network (EDRN)

PI: Ziding Feng PhD
Co-PI: Mark Thornquist PhD

The EDRN is a national network for the development, evaluation, and validation of biomarkers for early detection and risk assessment for cancer. Biomarks are cellular, biochemical, molecular, or genetic alterations by which a normal or abnormal biologic process can be recognized or monitored. Biomarkers are measurable in biological media, such as fluids, tissues, or cells. In addition to the National Cancer Institute, which funds the EDRN, there are four components to the network: 18 Biomarker Development Laboratories, 3 Biomarker Validation Laboratories, 9 Clinical and Epidemiologic Centers, and a Data Management and Coordinating Center (DMCC).

The DMCC, operated by FHCRC and UW statisticians and COMPASS, provides coordination and data management for the EDRN under the direction of the Steering Committee, and develops statistical and analytical methods in response to the scientific needs of the Network. Specific tasks performed at the DMCC include:

  • Network Coordination. Produce the Operating Policy and Procedure Manuals, assist in the development and implementation of collaborative study research protocols, develop and maintain a network secure web site and listserv, provide logistical and administrative support for meetings, and provide statistical support for collaborative studies within the Network and statistical consultation to the center-specific studies.


  • Data Management. Provide data management support for collaborative studies in the Network, including developing data collection protocols, monitoring adherence, developing and maintaining databases, and providing reports or study data as needed.


  • Theoretical and Applied Research. Develop statistical and analytical methods for biomarker evaluation and interpretation, specifically, focusing on the development and evaluation of flexible descriptive statistical methods 1) to assess the reliability and reproducibility of biomarkers and to identify factors that contribute to reducing reliability, 2) to assess the accuracy of a biomarker for cancer detection or cancer-risk assessment, and factors influencing its diagnostic potential, both when a gold standard exists, and when no gold standard exists, 3) to identify cancer heterogeneity for specific biomarkers, and 4) to identify biomarkers from microarray expression data.

    • The public website of EDRN is
    http://edrn.nci.nih.gov

    Contact:
    Royce Malnik
    rmalnik@fhcrc.org
    (206) 667-6972


    Fred Hutchinson Cancer Research Center
    1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
    ©2008 Fred Hutchinson Cancer Research Center, a nonprofit organization.
    Terms of Use & Privacy Policy.